This review aimed to present Chlamydomonas reinhardtii as an alternative for heterologous protein production, especially biopharmaceuticals, and its general characteristics when compared with other expression systems. The need produce proteins industrial interest, therapeutic ends, diagnostic kits has led the development of recombinant microalgal technology. technology presents some interesting...

The costs of developing the types of new drugs that have been pursued by traditional pharmaceutical firms have been estimated in a number of studies. However, similar analyses have not been published on the costs of developing the types of molecules on which biotech firms have focused. This study represents a first attempt to get a sense for the magnitude of the R&D costs associated with the di...

The biopharmaceuticals market is constantly growing. Despite their advantages over the conventional drugs, have short biological half-lifes, which can be increased using liposomes. However, common bulk methods to produce biopharmaceuticals-loaded liposomes result in lost of encapsulation efficiency (E.E.), resulting an expensive process. Herein, a therapeutic enzyme proposed, glass-capillary mi...